Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 20;9(4):1020. doi: 10.3390/cells9041020

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Silencing MALAT1 is associated with reduced CD133^highCD90^high HCC population with suppressed HCC tumorsphere formation in vitro. (A) Photo-images showing the effect of shMALAT1#1 and shMALAT1#2 on the size of tumorspheres formed and on the expression of CD133 and CD90 (left panel). Histograms show the effect of shMALAT1 #1 and #2 on number of tumorspheres formed (right panel). (B) SK-Hep1 or HepG2 cells transfected with shMALAT1#1 and shMALAT1#2 exhibited decreased HCC tumorsphere size and number in both primary and secondary generation tumorsphere. (C) Comparative flow-cytometry analysis CD133 and CD90 positivity in SK-Hep1 or HepG2 cells exposed to CDDP or transfected with shMALAT1#1 and shMALAT1#2. (D) Graphical representation of the correlation between MALAT1, CD133, and CD90. CDDP, cisplatin; *** p < 0.001.